WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

John Oyler Biography and Net Worth

Founder, Executive Chairman & CEO of BeiGene

John V. Oyler is our Co-Founder and Chairman, and has served as our Chief Executive Officer and a member of our Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Ma ssachusetts Institute of Technology and MBA from Stanford University.

What is John Oyler's net worth?: The estimated net worth of John Oyler is at least $2.13 million as of April 10th, 2024. Mr. Oyler owns 12,084 shares of BeiGene stock worth more than $2,132,826 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Oyler may own. Additionally, Mr. Oyler receives an annual salary of $2,050,000.00 as Founder, Executive Chairman & CEO at BeiGene. Learn More about John Oyler's net worth.
How old is John Oyler?: Mr. Oyler is currently 56 years old. There are 3 older executives and no younger executives at BeiGene. Learn More on John Oyler's age.
What is John Oyler's salary?: As the Founder, Executive Chairman & CEO of BeiGene, Ltd., Mr. Oyler earns $2,050,000.00 per year. Learn More on John Oyler's salary.
How do I contact John Oyler?: The corporate mailing address for Mr. Oyler and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on John Oyler's contact information.
Has John Oyler been buying or selling shares of BeiGene?: In the last ninety days, John Oyler has sold $1,433,958.50 in BeiGene stock. Most recently, John Oyler sold 6,175 shares of the business's stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a transaction totalling $1,433,958.50. Learn More on John Oyler's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (Founder, Executive Chairman & CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 19 times. They sold a total of 1,214,613 shares worth more than $226,013,519.58. The most recent insider tranaction occured on December, 10th when insider Xiaodong Wang sold 41,760 shares worth more than $7,804,944.00. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 12/10/2024.

John Oyler Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/8/2024	Sell	6,175	$232.22	$1,433,958.50
6/24/2024	Sell	2,789	$159.58	$445,068.62
4/10/2024	Sell	26,716	$148.89	$3,977,745.24	12,084
3/12/2024	Sell	37,668	$164.02	$6,178,305.36	12,332
1/10/2023	Sell	6,797	$248.52	$1,689,190.44
12/29/2022	Sell	1,716	$224.46	$385,173.36
12/27/2022	Sell	1,120	$224.29	$251,204.80
11/15/2022	Sell	25,000	$206.84	$5,171,000.00
9/20/2022	Sell	30,520	$153.50	$4,684,820.00	2,070,913
9/14/2021	Sell	195,477	$93.87	$18,349,425.99	2,267,161
9/2/2021	Sell	24,499	$328.21	$8,040,816.79	3,694,720
8/31/2021	Sell	111,081	$110.13	$12,233,350.53
8/4/2021	Sell	80,847	$150.97	$12,205,471.59	4,385,979
7/22/2021	Sell	69,216	$71.82	$4,971,093.12	5,849,945
7/20/2021	Sell	43,695	$132.26	$5,779,100.70	5,849,945
7/7/2021	Sell	300	$325.23	$97,569.00
9/29/2020	Sell	54,303	$280.39	$15,226,018.17	8,927,570
9/16/2020	Sell	27,275	$254.77	$6,948,851.75	9,633,509
9/14/2020	Sell	19,739	$250.25	$4,939,684.75	9,633,509
9/2/2020	Sell	61,042	$233.21	$14,235,604.82	10,689,473
8/31/2020	Sell	12,961	$240.86	$3,121,786.46	10,689,473
8/21/2020	Sell	40,788	$240.19	$9,796,869.72	11,483,019
8/19/2020	Sell	29,866	$234.56	$7,005,368.96	11,483,019
8/14/2020	Sell	8,705	$211.15	$1,838,060.75	12,681,320
8/12/2020	Sell	19,820	$212.10	$4,203,822.00	12,681,320
8/5/2020	Sell	17,254	$223.27	$3,852,300.58	13,239,904
8/3/2020	Sell	25,176	$221.78	$5,583,533.28	13,464,206
7/22/2020	Sell	27,748	$238.34	$6,613,458.32	13,991,473
7/20/2020	Sell	28,762	$251.85	$7,243,709.70	14,352,197
7/8/2020	Sell	17,529	$201.39	$3,530,165.31	15,069,472
7/6/2020	Sell	17,362	$197.11	$3,422,223.82	15,069,472
7/1/2020	Sell	3,816	$191.57	$731,031.12	15,770,354
6/29/2020	Sell	1,435	$192.60	$276,381.00	15,770,354
6/24/2020	Sell	14,381	$187.34	$2,694,136.54	15,838,617
6/22/2020	Sell	10,281	$182.43	$1,875,562.83	15,838,617
5/1/2020	Sell	4,635	$141.43	$655,528.05	16,366,833
12/17/2019	Sell	62,259	$160.62	$10,000,040.58	16,411,788
7/8/2019	Sell	3,106	$126.87	$394,058.22	17,221,155
5/1/2019	Sell	2,824	$125.18	$353,508.32
3/6/2019	Sell	25,499	$151.73	$3,868,963.27	17,298,245
3/4/2019	Sell	4,588	$152.01	$697,421.88	17,298,245
12/10/2018	Sell	4,138	$135.78	$561,857.64	17,420,172
11/28/2018	Sell	29,195	$143.66	$4,194,153.70	17,420,172
11/26/2018	Sell	9,078	$139.06	$1,262,386.68	17,420,172
7/16/2018	Sell	2,550	$164.12	$418,506.00
3/2/2018	Sell	99,000	$145.63	$14,417,370.00	93,883
2/28/2018	Sell	34,338	$146.69	$5,037,041.22	93,883
12/26/2017	Sell	20,137	$96.46	$1,942,415.02	110,179
12/8/2017	Sell	144,000	$93.95	$13,528,800.00	255,137
12/6/2017	Sell	31,446	$92.29	$2,902,151.34	255,137
11/29/2017	Sell	85,906	$84.66	$7,272,801.96	332,697
11/27/2017	Sell	16,581	$86.76	$1,438,567.56	332,697
11/15/2017	Sell	150,957	$80.50	$12,152,038.50	491,891
11/13/2017	Sell	25,054	$83.06	$2,080,985.24	491,891
7/6/2017	Sell	219,400	$64.82	$14,221,508.00	212,055
6/23/2017	Sell	98,500	$44.16	$4,349,760.00	88,535
5/1/2017	Sell	36,149	$40.47	$1,462,950.03	147,440
3/20/2017	Sell	31,989	$39.39	$1,260,046.71	197,640
3/6/2017	Sell	108,999	$40.91	$4,459,149.09	273,385
2/21/2017	Sell	64,963	$40.55	$2,634,249.65	378,383

John Oyler Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $176.50

$175.80

$179.25

50 Day Range

MA: $200.99

$174.72

$227.05

2 Week Range

Now: $176.50

$126.97

$248.16

Volume

337,011 shs

Average Volume

284,766 shs

Market Capitalization

$17.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Take these 4 steps today to protect your retirement NOW

John Oyler Biography and Net Worth

What is John Oyler's net worth?

How old is John Oyler?

What is John Oyler's salary?

How do I contact John Oyler?

Has John Oyler been buying or selling shares of BeiGene?

Who are BeiGene's active insiders?

Are insiders buying or selling shares of BeiGene?